Outcomes of Human Papilloma Virus Vaccination in a Private Women Health Clinic in Lebanon

dc.contributor.authorSeoud, Muhieddine A.F.
dc.contributor.authorJaafar, Iman
dc.contributor.authorGhanem, Rayan
dc.contributor.authorSoubhieh, Christiane
dc.contributor.authorAdra, Abdallah M.
dc.contributor.authorNassar, Anwar H.
dc.contributor.authorKhalil, Ali M.
dc.contributor.departmentObstetrics and Gynecology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:08:13Z
dc.date.available2025-01-24T12:08:13Z
dc.date.issued2022
dc.description.abstractObjectives. The study aims to report on the feasibility and associated adverse events of HPV-Vaccination (HPVV) in a private clinic setting in Lebanon and, when available, the results of subsequent cervical cancer screening. Methods. Opportunistic HPV vaccination is offered at the Women's Health Center of the AUBMC. We retrospectively reviewed the patients' demographic data, the incidence of adverse events, and their cytological screening. Results. A cohort of healthy women (n = 1013) aged 26.2 years (12-54 years) were opportunistically vaccinated with one of two HPV vaccines; 845 (83.4%) received the quadrivalent vaccine (Q4V), and 151 (14.1%) received the bivalent vaccine (B2V). The majority (75.8%) received three doses while 16% received two doses. Out of these women, 26.3% (267) became sexually active postvaccination (NS2), whereas 17% (174) were sexually active prior to vaccination (SA) and the rest 57% (572) reported no sexual activity (NS1). Among the SA group, 26% (46/147) presented with abnormal cytology at time of vaccination. As for the NS2 women, 5% (14/267) had subsequently abnormal screening within 37 (12-103) months following vaccination. Conclusions. In this observational study, we report the successful introduction of HPVV with negligible adverse events. The incidence of abnormal cervical cytology was low among our patients. © 2022 Muhieddine Seoud et al.
dc.identifier.doihttps://doi.org/10.1155/2022/7342061
dc.identifier.eid2-s2.0-85140834797
dc.identifier.urihttp://hdl.handle.net/10938/31760
dc.language.isoen
dc.publisherHindawi Limited
dc.relation.ispartofObstetrics and Gynecology International
dc.sourceScopus
dc.subjectHuman papilloma virus vaccine
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAnaphylaxis
dc.subjectArticle
dc.subjectCancer screening
dc.subjectChild
dc.subjectCohort analysis
dc.subjectColposcopy
dc.subjectControlled study
dc.subjectCytology
dc.subjectDemographics
dc.subjectDyspnea
dc.subjectFace edema
dc.subjectFemale
dc.subjectFollow up
dc.subjectHealth center
dc.subjectHuman
dc.subjectLebanon
dc.subjectMajor clinical study
dc.subjectObservational study
dc.subjectPapanicolaou test
dc.subjectPapillomavirus infection
dc.subjectRecurrent disease
dc.subjectRetrospective study
dc.subjectSexual intercourse
dc.subjectUterine cervix cancer
dc.subjectVaccination
dc.titleOutcomes of Human Papilloma Virus Vaccination in a Private Women Health Clinic in Lebanon
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-2014.pdf
Size:
523.88 KB
Format:
Adobe Portable Document Format